Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus temozolomide for recurrent glioblastoma
ChiCTR2300068731Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and temozolomide in glioblastoma (GBM), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall survival. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2300068731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068731.